Testosterone Therapy Lawsuit

FDA issued a Drug Safety Communication announcing it was evaluating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. The communication noted that two published studies raised concerns about cardiovascular risk. FDA directed manufacturers to update labeling and announced a formal safety review. This communication established that cardiovascular risk was recognized at the federal regulatory level — a key liability marker for lawsuits alleging failure to warn.

FDA convened its Endocrinologic and Metabolic Drugs Advisory Committee to evaluate cardiovascular safety evidence for testosterone products. The committee reviewed the TOM Trial data, the Vigen et al. JAMA 2013 study, and other post-market safety information. The committee voted that TRT labeling failed to adequately communicate cardiovascular risk and that approved indications should be narrowed. This advisory committee meeting preceded and directly informed the 2015 label change mandate — establishing regulatory knowledge and the inadequacy of existing warnings.

FDA mandated that all testosterone product labels include a warning about venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). This class-wide labeling change applied to every FDA-approved testosterone product. The mandate constituted an official regulatory finding that VTE risk was real, significant, and insufficiently disclosed by prior labeling — directly supporting failure-to-warn claims for patients who suffered DVT or PE before this date.

FDA required manufacturers to revise labels to restrict approved use to hypogonadism caused by underlying medical conditions (not age-related decline) and to add a statement that the cardiovascular risk of testosterone therapy had not been established. This restriction directly repudiated the 'Low T' marketing campaigns that drove mass prescribing, confirming that millions of men were prescribed testosterone outside of medically valid indications. The failure to restrict indications earlier — despite the 2010 TOM Trial evidence — supports claims that FDA-mandated warnings were unreasonably delayed.

The Testosterone in Older Men with Mobility Limitations (TOM) Trial, funded by the National Institutes of Health (NIH) and published in the New England Journal of Medicine, was stopped early by its Data Safety Monitoring Board after men in the testosterone group experienced significantly higher rates of cardiovascular adverse events compared to placebo. Events included heart attack, stroke, arrhythmia, and death. This landmark finding — published February 2010 — put manufacturers on notice of serious cardiovascular risk more than four years before the FDA's first Drug Safety Communication, a critical timeline fact for knowledge-based claims.